Clin Cancer Res 2005, 11: 6459–6465.PubMedCrossRef 8. Macri A, Versaci A, Lupo G, Trimarchi G, Tomasello C, Loddo S, Sfuncia G, Caminiti R, Teti D, Famulari C: Role Birinapant cell line of osteopontin in breast cancer patients. Tumori 2009, 95: 48–52.PubMed 9. Yeatman TJ, Chambers AF: Osteopontin and colon cancer progression. Clin Exp Metastasis 2003, 20: 85–90.PubMedCrossRef 10. Stein GS, Stein JL, Van

Wijnen AJ, Lian JB, Montecino M, Croce CM, Choi JY, Ali SA, Pande S, Hassan MQ, et al.: Transcription factor-mediated epigenetic regulation of cell growth and phenotype for biological control and cancer. Adv Enzyme Regul 50: 160–167. 11. Kajanne R, Miettinen P, Tenhunen M, Leppa S: Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells. Int J Oncol 2009, 35: 1175–1182.PubMed 12. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X: Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin Cancer Res 2009, 15: 492–501.PubMedCrossRef 13. Blyth K, Cameron ER, Neil JC: The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer 2005, 5: 376–387.PubMedCrossRef 14. Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, Liu YK, Tang ZY: Stepwise metastatic human hepatocellular Src inhibitor carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic

GBA3 characteristics. J Cancer Res Clin Oncol 2004, 130: 460–468.PubMedCrossRef 15. Deregibus MC, Cantaluppi V, Doublier S, Brizzi MF, Deambrosis I, Albini A, Camussi G: HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi’s sarcoma cells. J Biol Chem 2002, 277: 25195–25202.PubMedCrossRef 16. Hijiya N,

Setoguchi M, Matsuura K, Higuchi Y, Akizuki S, Yamamoto S: Cloning and characterization of the human osteopontin gene and its promoter. Biochem J 1994, 303 (Pt 1) : 255–262.PubMed 17. Shevde LA, Das S, Clark DW, Samant RS: Osteopontin: An Effector and an Effect of Tumor Metastasis. Curr Mol Med 2010, 10 (1) : 71–81.PubMedCrossRef 18. Johnston NI, Gunasekharan VK, Ravindranath A, O’Connell C, Johnston PG, El-Tanani MK: Osteopontin as a target for cancer therapy. Front Biosci 2008, 13: 4361–4372.PubMedCrossRef 19. Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC: Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 2007, 11: 81–90.PubMedCrossRef 20. Wai PY, Kuo PC: Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008, 27: 103–118.PubMedCrossRef 21. Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G, Kunz M: The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog 2009, 48: 14–23.PubMedCrossRef 22. Ramsay RG, Gonda TJ: MYB function in normal and cancer cells.